NCT02378389Unknown1 期
A Phase I Study of Pyrotinib In Combination With Docetaxel In Patients With HER2 Positive Advanced Gastric Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 入组人数
- 28
- 试验地点
- 4
- 主要终点
- The maximum-tolerated dose (MTD) of Pyrotinib and that of Pyrotinib with Docetaxel in patients with HER2 positive advanced gastric cancer
研究概览
简要总结
Pyrotinib is an oral tyrosine kinase inhibitor targeting both EGFR and HER-2 receptors. This study is designed to evaluate the safety and tolerability of Pyrotinib or Pyrotinib in combination with Docetaxel in patients with HER2 positive advanced gastric cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged ≥18 and ≤70 years.
- •ECOG performance status of 0 to
- •Life expectancy of more than 12 weeks.
- •At least one measurable lesion exists.(RECIST 1.1).
- •Histologically or cytologic confirmed HER2 positive advanced gastric cancer (including adenocarcinoma of esophageal-gastric junction), with clinical phase III/IV.
- •No severe impairment of liver and kidney function, required laboratory values including following parameters:ANC:≥1.5x109/L, Platelet count:≥90x109/L, Hemoglobin:≥9.0 g/dL, Total bilirubin:≤1xULN, ALT and AST: ≤1.5xULN (for patients with liver metastases,ALT and AST:≤5xULN), ALP:≤2.5xULN, BUN and creatine:≤1xULN, creatine clearance rate:≥50 mL/min, LVEF:≥50%, QTcF:<450 ms (male), <470 ms (female),INR:≤1.5xULN, APTT:≤1.5xULN.
- •Signed informed consent.
- •For subjects treated by Pyrotinib only:
- •Failed or intolerable of prior therapies.
- •For subjects treated by Pyrotinib with Docetaxel:
- •Failed or intolerable of prior therapies, no previous treatment of taxane, no previous treatment of HER2 targeted inhibitors.
排除标准
- •Subjects with third space fluid that can not be controled by drainage or other methods.
- •Subjects that are unable to swallow tablets, or dysfunction of gastrointestinal absorption.
- •Steroid treatment for more than 50 days, or in need of long-term use of steroids.
- •Less than 4 weeks from the last radiotherapy,chemotherapy，surgery，hermone treatment,target therapy, or less than 6 weeks from the nitrosoureas or mitomycin chemotherapy.
- •Less than 4 weeks from the last clinical trial or adverse events of previous trials (not including alopecia or asthenia).
- •Subjects with uncontrolled hypokalemia and hypomagnesemia before study entry.
- •Subjects who can not interrupt using of the drugs causing QT prolongation during study.
- •Subjects with intracranial lesions (by MRI or CT).
- •Subjects suffered from other malignancies during last 5 years, not including cervical carcinoma in situ, basal cell carcinoma or squamous cell carcinoma.
- •Subjects with bone or skin as the only target lesion.
- •Receiving any other antitumor therapy.
- •Known history of hypersensitivity to any of the components or metabolites of the investigational drugs or to Tween-
- •Subjects with clear tendency of gastointestinal bleeding. Including the following: subjects with local active ulcer lesions and fecal occult blood (++) are excluded; subjects with less than 2 months from the last history of black stools or haematemesis are excluded; for subjects with fecal occult blood (+) and primary lesion not resected, endoscopy is required,if gastric ulcer is found and the principal investigator of the site consider possible occurence of gastointestinal bleeding, the subject should be excluded.
- •Ongoing infection or peripheral neuropathy (determined by investigator).
- •History of immunodeficiency, including HIV-positive, suffering from other acquired, congenital immunodeficiency disease, or history of organ transplantation.
- •Subjects had any heart disease, including: (1) angina; (2) requiring medication or clinically significant arrhythmia; (3) myocardial infarction; (4) heart failure; (5) Any heart diseases judged by investigator as unsuitable to participate in the trial.
- •Female patients who are pregnancy, lactation or women who are of childbearing potential tested positive in baseline pregnancy test or reluctant to take effective contraceptive measures throughout the trial period.
- •Evidence of significant medical illness that in the investigator's judgment will substantially increase the risk associated with the subject's participation in and completion of the study. Examples include, but are not limited to,hypertension, severe diabetes, or thyroid disease.
- •Alcoholism, smoking (daily ≥ 5 roots) and other bad habits.
- •Known history of neurological or psychiatric disease, including epilepsy or dementia.
研究组 & 干预措施
Pyrotinib/Pyrotinib with Docetaxel
Experimental
Subjects would be treated with Pyrotinib (Part 1) or Pyrotinib with Docetaxel (Part 2). A subject is only allowed to participant in one part of this trial.
干预措施: Pyrotinib/Pyrotinib with Docetaxel (Drug)
结局指标
主要结局
The maximum-tolerated dose (MTD) of Pyrotinib and that of Pyrotinib with Docetaxel in patients with HER2 positive advanced gastric cancer
时间窗: 21 days
MTD will be defined as the maximum dose level at which no more than one subject out of three experience has a dose-limiting toxicity (DLT) upon completing one treatment cycle. DLT was defined as the certain AEs which were observed during the first cycle (D1-D21) of treatment
次要结局
- Cmax of Pyrotinib and Pytotinib with Docetaxel in patients with HER2 positive advanced gastric cancer(12 months)
- T1/2 of Pyrotinib and Pytotinib with Docetaxel in patients with HER2 positive advanced gastric cancer(12 months)
- R of Pyrotinib and Pytotinib with Docetaxel in patients with HER2 positive advanced gastric cancer(12 months)
- Tmax of Pyrotinib and Pytotinib with Docetaxel in patients with HER2 positive advanced gastric cancer(12 months)
- AUCss of Pyrotinib and Pytotinib with Docetaxel in patients with HER2 positive advanced gastric cancer(12 months)
- the number of participants with adverse event(12 months)
- preliminary antitumor activity for the regimen(12 months)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
Study Evaluating Pyrotinib in Combination With Capecitabine In Patients With HER2 Positive Metastatic Breast CancerMetastatic Breast CancerNCT02361112Jiangsu HengRui Medicine Co., Ltd.38
已完成
2 期
Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.HER2 Positive Breast CancerNCT03735966Henan Cancer Hospital75
已完成
1 期
Study of Pyrotinib in Patients With Human Epidermalgrowth Factor Receptor 2 (HER2) Positive Advanced Breast CancerBreast CancerNCT01937689Jiangsu HengRui Medicine Co., Ltd.40
Unknown
3 期
Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)HER2 Positive Metastatic Breast CancerNCT03080805Jiangsu HengRui Medicine Co., Ltd.240
Unknown
1 期
A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or TrastuzumabHER2 Positive Metastatic Breast CancerNCT02422199Jiangsu HengRui Medicine Co., Ltd.128